Abbott Laboratories (ABT), (founding name: Abbott Alkaloid Company) is a global pharmaceutical company with around 73,000 employees in 150 countries. Abbott was founded in 1888 by Wallace C. Abbott (1857-1921) and is headquartered in Abbott Park, a northern suburb of Chicago, Illinois.
Table of Contents
F1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
⌧
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2021
OR
◻
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File No. 1-2189
ABBOTT LABORATORIES
An Illinois Corporation
I.R.S. Employer Identification No.
36-0698440
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
Telephone: (224) 667-6100
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common Shares, Without Par Value
ABT
New York Stock ExchangeChicago Stock Exchange, Inc.
Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer ☒
Accelerated Filer ☐
Non-Accelerated Filer ☐
Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of June 30, 2021, Abbott Laboratories had 1,772,817,349 common shares without par value outstanding.
Abbott Laboratories
Part I - Financial Information
Page
Item 1. Financial Statements and Supplementary Data
Condensed Consolidated Statement of Earnings
3
Condensed Consolidated Statement of Comprehensive Income
4
Condensed Consolidated Balance Sheet
5
Condensed Consolidated Statement of Shareholders’ Investment
6
Condensed Consolidated Statement of Cash Flows
8
Notes to the Condensed Consolidated Financial Statements
9
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
22
Item 4. Controls and Procedures
28
Part II - Other Information
Item 1. Legal Proceedings
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Item 6. Exhibits
29
Signature
30
2
Abbott Laboratories and Subsidiaries
(Unaudited)
(dollars in millions except per share data; shares in thousands)
Three Months Ended June 30
Six Months Ended June 30
2021
2020
Net sales
$
10,223
7,328
20,679
15,054
Cost of products sold, excluding amortization of intangible assets
4,947
3,263
9,348
6,544
Amortization of intangible assets
504
553
1,013
1,114
Research and development
654
564
1,308
1,142
Selling, general and administrative
2,726
2,276
5,509
4,824
Total operating cost and expenses
8,831
6,656
17,178
13,624
Operating earnings
1,392
672
3,501
1,430
Interest expense
134
269
273
Interest (income)
(11)
(9)
(22)
(27)
Net foreign exchange (gain) loss
—
(1)
Other (income) expense, net
(79)
(140)
21
Earnings from continuing operations before taxes
1,348
526
3,391
1,159
Tax expense (benefit) on earnings from continuing operations
159
409
78
Earnings from continuing operations
1,189
537
2,982
1,081
Earnings from discontinued operations, net of tax
20
Net Earnings
1,101
Basic Earnings Per Common Share —
Continuing operations
0.67
0.30
1.67
0.61
Discontinued operations
0.01
Net earnings
0.62
Diluted Earnings Per Common Share —
0.66
1.66
0.60
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share
1,779,203
1,772,953
1,778,049
1,770,970
Dilutive Common Stock Options
14,076
12,087
14,369
11,882
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options
1,793,279
1,785,040
1,792,418
1,782,852
Outstanding Common Stock Options Having No Dilutive Effect
2,720
50
2,694
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
(dollars in millions)
Foreign currency translation gain (loss) adjustments
165
355
(371)
(789)
Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $18 and $36 in 2021 and $13 and $28 in 2020
48
37
133
94
Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $2 and $48 in 2021 and $(29) and $19 in 2020
(86)
118
80
Other comprehensive income (loss)
219
306
(120)
(615)
Comprehensive Income
1,408
843
2,862
486
June 30,
December 31,
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:
Cumulative foreign currency translation (loss) adjustments
(5,230)
(4,859)
Net actuarial (losses) and prior service (costs) and credits
(3,738)
(3,871)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other
(98)
(216)
Accumulated other comprehensive income (loss)
(9,066)
(8,946)
Assets
Current Assets:
Cash and cash equivalents
8,658
6,838
Short-term investments
286
310
Trade receivables, less allowances of $498 in 2021 and $460 in 2020
6,113
6,414
Inventories:
Finished products
3,118
3,030
Work in process
796
712
Materials
1,525
1,270
Total inventories
5,439
5,012
Prepaid expenses and other receivables
2,131
1,867
Total Current Assets
22,627
20,441
Investments
805
821
Property and equipment, at cost
19,074
18,793
Less: accumulated depreciation and amortization
10,258
9,764
Net property and equipment
8,816
9,029
Intangible assets, net of amortization
13,681
14,784
Goodwill
23,485
23,744
Deferred income taxes and other assets
3,855
3,729
73,269
72,548
Liabilities and Shareholders’ Investment
Current Liabilities:
Short-term borrowings
199
213
Trade accounts payable
4,017
3,946
Salaries, wages and commissions
1,248
1,416
Other accrued liabilities
5,354
5,165
Dividends payable
799
798
Income taxes payable
242
362
Current portion of long-term debt
755
7
Total Current Liabilities
12,614
11,907
Long-term debt
17,547
18,527
Post-employment obligations, deferred income taxes and other long-term liabilities
9,079
9,111
Commitments and Contingencies
Shareholders’ Investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2021: 1,982,553,488; 2020: 1,981,156,896
24,153
24,145
Common shares held in treasury, at cost — Shares: 2021: 209,736,139; 2020: 209,926,622
(10,340)
(10,042)
Earnings employed in the business
29,053
27,627
Total Abbott Shareholders’ Investment
33,800
32,784
Noncontrolling Interests in Subsidiaries
229
Total Shareholders’ Investment
34,029
33,003
(in millions except shares and per share data)
Common Shares:
Balance at March 31
Shares: 2021: 1,982,205,491; 2020: 1,978,112,501
24,023
23,731
Issued under incentive stock programs
Shares: 2021: 347,997; 2020: 1,481,878
18
66
Share-based compensation
119
105
Issuance of restricted stock awards
(7)
Balance at June 30
Shares: 2021: 1,982,553,488; 2020: 1,979,594,379
23,893
Common Shares Held in Treasury:
Shares: 2021: 205,385,343; 2020: 209,267,175
(9,845)
(9,913)
Shares: 2021: 159,644; 2020: 212,973
10
Purchased
Shares: 2021: 4,510,440; 2020: 10,178
(503)
Shares: 2021: 209,736,139; 2020: 209,064,380
(9,904)
Earnings Employed in the Business:
28,669
25,786
Cash dividends declared on common shares (per share — 2021: $0.45; 2020: $0.36)
(801)
(640)
Effect of common and treasury share transactions
(4)
(14)
25,669
Accumulated Other Comprehensive Income (Loss):
(9,285)
(9,386)
(9,080)
Noncontrolling Interests in Subsidiaries:
226
209
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases
11
220
The accompanying notes to condensed consolidated financial statements are an integral part of this statement.
Balance at January 1
Shares: 2021: 1,981,156,896; 2020: 1,976,855,085
23,853
Shares: 2021: 1,396,592; 2020: 2,739,294
65
423
350
(480)
(429)
Shares: 2021: 209,926,622; 2020: 214,351,838
(10,147)
Shares: 2021: 4,978,431; 2020: 5,546,599
239
263
Shares: 2021: 4,787,948; 2020: 259,141
(537)
(20)
25,847
Impact of adoption of new accounting standard
(5)
Cash dividends declared on common shares (per share — 2021: $0.90; 2020: $0.72)
(1,604)
(1,281)
(8,465)
Cash Flow From (Used in) Operating Activities:
Adjustments to reconcile net earnings to net cash from operating activities —
Depreciation
795
539
420
348
Trade receivables
200
127
Inventories
(542)
(987)
Other, net
(103)
(205)
Net Cash From Operating Activities
4,765
2,037
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment
(810)
(1,002)
Acquisitions of businesses and technologies, net of cash acquired
(15)
(32)
Proceeds from business dispositions
Sales (purchases) of other investment securities, net
81
Other
Net Cash (Used in) Investing Activities
(686)
(1,012)
Cash Flow From (Used in) Financing Activities:
Net borrowings (repayments) of short-term debt and other
31
Proceeds from issuance of long-term debt
1,279
Repayments of long-term debt
(2)
Purchases of common shares
(746)
(240)
Proceeds from stock options exercised
103
146
Dividends paid
(1,603)
(1,280)
Net Cash (Used in) Financing Activities
(2,231)
(77)
Effect of exchange rate changes on cash and cash equivalents
(28)
(45)
Net Increase in Cash and Cash Equivalents
1,820
903
Cash and Cash Equivalents, Beginning of Year
3,860
Cash and Cash Equivalents, End of Period
4,763
June 30, 2021
Note 1 — Basis of Presentation
The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2020. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.
Note 2 — New Accounting Standards
Recently Adopted Accounting Standards
In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. Abbott adopted the standard on January 1, 2021. The new standard did not have an impact on its condensed consolidated financial statements.
Note 3 — Revenue
Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Note 3 — Revenue (Continued)
The following tables provide detail by sales category:
Three Months Ended June 30, 2021
Three Months Ended June 30, 2020
(in millions)
U.S.
Int’l
Total
Established Pharmaceutical Products —
Key Emerging Markets
915
764
265
249
1,180
Nutritionals —
Pediatric Nutritionals
528
565
1,093
484
540
1,024
Adult Nutritionals
345
670
1,015
324
535
859
873
1,235
2,108
808
1,075
1,883
Diagnostics —
Core Laboratory
283
1,023
1,306
289
698
987
Molecular
196
290
144
215
359
Point of Care
97
40
137
79
39
Rapid Diagnostics
681
833
1,514
185
530
1,155
2,092
3,247
857
1,137
1,994
Medical Devices —
Rhythm Management
298
567
216
401
Electrophysiology
278
487
120
179
299
Heart Failure
168
59
227
115
43
158
Vascular
246
451
697
313
481
Structural Heart
191
231
422
91
132
223
Neuromodulation
166
44
210
85
106
Diabetes Care
767
1,056
202
1,538
2,128
3,666
966
1,457
2,423
15
3,581
6,642
2,638
4,690
Six Months Ended June 30, 2021
Six Months Ended June 30, 2020
1,736
1,577
514
480
2,250
2,057
1,036
1,123
2,159
1,002
1,111
2,113
673
1,312
1,985
618
1,674
1,709
2,435
4,144
1,620
2,167
3,787
554
1,934
2,488
556
1,420
1,976
468
737
498
189
77
266
182
74
256
1,784
1,986
3,770
713
377
1,090
2,796
4,465
7,261
1,660
2,160
3,820
510
576
1,086
413
462
875
388
918
284
403
687
108
421
267
361
465
867
1,332
398
708
1,106
360
439
314
541
311
83
394
222
61
542
1,494
2,036
1,119
1,507
2,889
4,097
6,986
2,199
3,161
5,360
25
13
38
7,419
13,260
5,494
9,560
Remaining Performance Obligations
As of June 30, 2021, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $3.9 billion in the Diagnostics segment and approximately $414 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 60 percent of these remaining performance obligations over the next 24 months, approximately 16 percent over the subsequent 12 months and the remainder thereafter.
These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.
Other Contract Assets and Liabilities
Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were not significant.
Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices reportable segment when payment is received upfront for various multi-period extended service arrangements.
Changes in the contract liabilities during the period are as follows:
Contract Liabilities:
Balance at December 31, 2020
405
Unearned revenue from cash received during the period
280
Revenue recognized related to contract liability balance
(279)
Balance at June 30, 2021
406
Note 4 — Supplemental Financial Information
Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Earnings from Continuing Operations allocated to common shares for the three months ended June 30, 2021 and 2020 were $1.184 billion and $534 million, respectively, and for the six months ended June 30, 2021 and 2020 were $2.969 billion and $1.075 billion, respectively. Net earnings allocated to common shares for the three months ended June 30, 2021 and 2020 were $1.184 billion and $534 million, respectively, and for the six months ended June 30, 2021 and 2020 were $2.969 billion and $1.095 billion, respectively.
Earnings from discontinued operations, net of tax, in the first six months of 2020 include the recognition of $20 million of tax benefits as a result of the resolution of various tax positions related to the previous sale of a business that was reported as a discontinued operation.
Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first six months of 2021 includes $80 million of pension contributions and the payment of cash taxes of approximately $715 million. The first six months of 2020 includes $335 million of pension contributions and the payment of cash taxes of approximately $285 million.
The following summarizes the activity for the first six months of 2021 related to the allowance for doubtful accounts as of June 30, 2021:
Allowance for Doubtful Accounts:
288
Provisions/charges to income
Amounts charged off and other deductions
12
Note 4 — Supplemental Financial Information (Continued)
The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.
The components of long-term investments as of June 30, 2021 and December 31, 2020 are as follows:
Long-term Investments:
Equity securities
754
776
51
45
The decrease in Abbott’s long-term investments as of June 30, 2021 versus the balance as of December 31, 2020 primarily relates to the sale of an equity method investment.
Abbott’s equity securities as of June 30, 2021, include $388 million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. (St. Jude Medical) business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.
Abbott also holds certain investments as of June 30, 2021 with a carrying value of $260 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately $91 million that do not have a readily determinable fair value. An approximately $60 million impairment of an investment was recorded in the second quarter of 2020 for which Abbott had previously recorded an unrealized gain of approximately $50 million in 2018.
Note 5 — Changes in Accumulated Other Comprehensive Income (Loss)
The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:
Cumulative Gains (Losses)
Cumulative Foreign
Net Actuarial (Losses) and
on Derivative Instruments
Currency Translation
Prior Service (Costs) and
Designated as Cash Flow
Adjustments
Credits
Hedges
(5,395)
(6,068)
(3,786)
(3,483)
(104)
Other comprehensive income (loss) before reclassifications
(12)
(67)
Amounts reclassified from accumulated other comprehensive income
60
46
34
(19)
Net current period comprehensive income (loss)
(5,713)
(3,446)
Note 5 — Changes in Accumulated Other Comprehensive Income (Loss) (Continued)
(4,924)
(3,540)
68
109
123
96
(29)
Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 12 for additional details.
Note 6 — Goodwill and Intangible Assets
The total amount of goodwill reported was $23.5 billion at June 30, 2021 and $23.7 billion at December 31, 2020. Foreign currency translation adjustments decreased goodwill by approximately $259 million in the first six months of 2021. The amount of goodwill related to reportable segments at June 30, 2021 was $2.9 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $3.8 billion for the Diagnostic Products segment, and $16.4 billion for the Medical Devices segment. There was no reduction of goodwill relating to impairments in the first six months of 2021.
Indefinite-lived intangible assets, which relate to in-process R&D (IPR&D) acquired in a business combination, were approximately $947 million as of June 30, 2021 and $1.2 billion at December 31, 2020. The decrease is due to IPR&D assets primarily related to the Medical Devices segment that became amortizable in the second quarter of 2021.
The gross amount of amortizable intangible assets, primarily product rights and technology was $27.8 billion as of June 30, 2021 and December 31, 2020, and accumulated amortization was $15.1 billion as of June 30, 2021 and $14.2 billion as of December 31, 2020. Foreign currency translation adjustments decreased intangible assets by $83 million in the first six months of 2021. In the second quarter of 2021, an asset impairment related to the Established Pharmaceutical Products segment decreased intangible assets by $11 million. The impairment was recorded in the Cost of products sold, excluding amortization of intangible assets line of Abbott’s Condensed Consolidated Statement of Earnings. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.0 billion in 2021 and 2022, and $1.9 billion in 2023, 2024, and 2025.
Note 7 — Restructuring Plans
On May 27, 2021, Abbott management approved a restructuring plan related to its Diagnostic Products segment to align its manufacturing network for COVID-19 diagnostic tests with changes in projected testing demand driven by several factors, including significant reductions in cases in the U.S. and other major developed countries, the accelerated rollout of COVID-19 vaccines globally and the U.S. health authority’s updated guidance on testing for fully vaccinated individuals. Abbott estimates that the total pre-tax cost to implement this restructuring plan will be approximately $500 million to $625 million, including fixed asset write-downs of $80 million to $115 million, inventory-related charges of $250 million to $260 million, and other exit costs of $170 million to $250 million. Other exit costs include contract cancellation and employee-related costs. Actions associated with this plan are expected to be substantially complete by the end of 2021.
14
Note 7 — Restructuring Plans (Continued)
In the second quarter of 2021, Abbott recorded charges of $499 million under this plan in Cost of products sold. The charge recognized in the second quarter includes fixed asset write-downs of $80 million, inventory-related charges of $248 million, and other exit costs, which include contract cancellations and employee-related costs of $171 million. Other exit costs will result in future cash outlays that are expected to be made primarily over the next 6 months. The following summarizes the activity for the first six months of 2021 related to this restructuring action and the status of the related accruals as of June 30, 2021:
Inventory
Related
Fixed Asset
Other Exit
Charges
Write-Downs
Costs
Restructuring charges recorded in 2021
248
171
499
Payments
Other-non-cash
(248)
(80)
(328)
Accrued balance at June 30, 2021
152
From 2017 to 2021, Abbott management approved restructuring plans as part of the integration of the acquisitions of St. Jude Medical into the Medical Devices segment, and Alere Inc. (Alere) into the Diagnostic Products segment, in order to leverage economies of scale and reduce costs. As of December 31, 2020, the accrued balance associated with these actions was $25 million. In the first six months of 2021, charges of $4 million were recognized, of which $1 million is recorded in Cost of products sold and $3 million as Selling, general and administrative expense. As of June 30, 2021, the accrued liabilities remaining in the Condensed Consolidated Balance Sheet related to these actions total $15 million and primarily represent severance obligations.
From 2017 to 2020, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in various Abbott businesses including the nutritional, established pharmaceuticals and vascular businesses. In the first six months of 2021, charges of $1 million were recognized as Cost of products sold. The following summarizes the activity for the first six months of 2021 related to these restructuring actions and the status of the related accrual as of June 30, 2021:
Accrued balance at December 31, 2020
70
1
Payments and other adjustments
(24)
47
Note 8 — Incentive Stock Programs
In the first six months of 2021, Abbott granted 2,730,398 stock options, 478,490 restricted stock awards and 4,624,439 restricted stock units under its incentive stock program. At June 30, 2021, approximately 101 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at June 30, 2021 is as follows:
Outstanding
Exercisable
Number of shares
30,091,814
23,273,096
Weighted average remaining life (years)
6.0
5.2
Weighted average exercise price
62.45
51.56
Aggregate intrinsic value (in millions)
1,631
1,498
The total unrecognized share-based compensation cost at June 30, 2021 amounted to approximately $645 million which is expected to be recognized over the next three years.
Note 9 — Debt and Lines of Credit
On June 24, 2020, Abbott completed the issuance of $1.3 billion aggregate principal amount of senior notes, consisting of $650 million of its 1.15% Notes due 2028 and $650 million of its 1.40% Notes due 2030.
Note 10 — Financial Instruments, Derivatives and Fair Value Measures
Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $8.8 billion at June 30, 2021 and $8.1 billion at December 31, 2020 are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of June 30, 2021 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.
Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At June 30, 2021 and December 31, 2020, Abbott held the gross notional amounts of $10.0 billion and $11.0 billion, respectively, of such foreign currency forward exchange contracts.
Abbott has designated a yen-denominated, 5-year term loan of approximately $540 million and $577 million as of June 30, 2021 and December 31, 2020, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.
Abbott is a party to interest rate hedge contracts totaling approximately $2.9 billion at June 30, 2021 and December 31, 2020 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.
The following table summarizes the amounts and location of certain derivative financial instruments as of June 30, 2021 and December 31, 2020:
Fair Value - Assets
Fair Value - Liabilities
Dec. 31,
Balance Sheet Caption
Interest rate swaps designated as fair value hedges
143
Foreign currency forward exchange contracts:
Hedging instruments
98
151
433
Others not designated as hedges
67
Debt designated as a hedge of net investment in a foreign subsidiary
n/a
577
300
758
16
Note 10 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and six months ended June 30, 2021 and 2020.
Gain (loss) Recognized in Other
Income (expense) and Gain (loss)
Comprehensive Income (loss)
Reclassified into Income
Three Months
Six Months
Ended June 30
Income Statement Caption
Foreign currency forward exchange contracts designated as cash flow hedges
(88)
(89)
138
(92)
(115)
42
Cost of products sold
(10)
27
195
Losses of $16 million and gains of $67 million were recognized in the three months ended June 30, 2021 and 2020, respectively, related to foreign currency forward exchange contracts not designated as a hedge. Gains of $33 million and losses of $98 million were recognized in the six months ended June 30, 2021 and 2020, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.
The carrying values and fair values of certain financial instruments as of June 30, 2021 and December 31, 2020 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.
December 31, 2020
Carrying
Fair
Value
Long-term Investment Securities:
Total Long-term Debt
(18,302)
(21,592)
(18,534)
(22,809)
Foreign Currency Forward Exchange Contracts:
Receivable position
141
90
(Payable) position
(218)
(498)
Interest Rate Hedge Contracts:
The fair value of the debt was determined based on significant other observable inputs, including current interest rates.
17
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:
Basis of Fair Value Measurement
Quoted
Significant
Prices in
Active
Observable
Unobservable
Balances
Markets
Inputs
June 30, 2021:
Interest rate swap derivative financial instruments
Foreign currency forward exchange contracts
Total Assets
Fair value of hedged long-term debt
218
Contingent consideration related to business combinations
Total Liabilities
3,267
3,200
December 31, 2020:
386
686
3,049
3,615
3,547
The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value.
Note 11 — Litigation and Environmental Matters
Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.
Note 11 — Litigation and Environmental Matters (Continued)
Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $255 million to $280 million. The recorded accrual balance at June 30, 2021 for these proceedings and exposures was approximately $265 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.
Note 12 — Post-Employment Benefits
Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized in continuing operations for the three and six months ended June 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:
Defined Benefit Plans
Medical and Dental Plans
Service cost — benefits earned during the period
23
Interest cost on projected benefit obligations
62
124
149
Expected return on plan assets
(211)
(191)
(422)
(383)
Net amortization of:
Actuarial loss, net
64
Prior service cost (credit)
Net cost — continuing operations
26
58
Abbott funds its domestic defined benefit plans according to Internal Revenue Service funding limitations. International pension plans are funded according to similar regulations. In the first six months of 2021 and 2020, $80 million and $335 million, respectively, were contributed to defined benefit plans. Contributions made to post-employment medical and dental plans in the first six months of 2020 were $11 million. No contributions were made to the post-employment medical and dental plans in the first six months of 2021.
Note 13 — Taxes on Earnings
Taxes on earnings from continuing operations reflect the estimated annual effective rates and include charges for interest and penalties. In the first six months of 2021 and 2020, taxes on earnings from continuing operations include approximately $90 million and $67 million, respectively, in excess tax benefits associated with share-based compensation. In the first six months of 2020, taxes on earnings from continuing operations also include approximately $81 million in tax benefits related to the settlement of the former St. Jude Medical consolidated group’s 2014 through 2016 federal income tax returns in the U.S. Earnings from discontinued operations, net of tax, in the first six months of 2020 reflect the recognition of $20 million of net tax benefits primarily as a result of the resolution of various tax positions related to prior years.
Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $80 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.
19
Note 14 — Segment Information
Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.
Abbott’s reportable segments are as follows:
Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.
Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.
Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, physician offices and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.
Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology and Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.
Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.
Note 14 — Segment Information (Continued)
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.
Net Sales to External Customers
Operating Earnings
Established Pharmaceutical Products
206
389
387
Nutritional Products
490
474
957
933
Diagnostic Products
1,076
522
2,777
927
Medical Devices
1,208
391
2,215
1,194
Total Reportable Segments
10,201
7,313
20,641
15,024
2,994
1,593
6,338
3,441
Corporate functions and benefit plan costs
(132)
(106)
(246)
(238)
Net interest expense
(123)
(125)
(247)
Share-based compensation (a)
(420)
(348)
(504)
(553)
(1,013)
(1,114)
Other, net (b)
(755)
(168)
(1,021)
(336)
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations
Financial Review - Results of Operations
Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott’s products under a contract most impact which products are sold; price controls, competition and rebates most impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. Abbott’s primary products are medical devices, diagnostic testing products, nutritional products and branded generic pharmaceuticals.
The following table details sales by reportable segment for the three and six months ended June 30. Percent changes are versus the prior year and are based on unrounded numbers.
Ended
Impact of
Total Change
Foreign
Excl. Foreign
Change
Exchange
16.4
%
1.9
14.5
11.9
2.4
9.5
62.8
5.6
57.2
51.3
6.2
45.1
39.5
4.5
35.0
62.5
4.6
57.9
Net Sales
Total U.S.
35.8
Total International
41.6
7.0
34.6
9.4
(0.9)
10.3
1.4
8.0
90.0
5.3
84.7
30.3
5.1
25.2
37.4
3.5
33.9
34.0
4.1
29.9
38.7
5.4
33.3
Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
The 35.0 percent increase in total net sales during the second quarter of 2021, excluding the impact of foreign exchange, reflected demand for Abbott’s tests to detect COVID-19 as well as other growth across Abbott’s reportable segments. During the second quarter of 2021, Abbott’s COVID-19 testing-related sales totaled approximately $1.3 billion led by combined sales of approximately $1.0 billion related to Abbott’s BinaxNOW®, Panbio®, and ID NOW® rapid-testing platforms. During the second quarter of 2020, COVID-19 testing related sales totaled approximately $0.6 billion. Excluding the impact of COVID-19 testing-related sales, Abbott’s total net sales increased 33.2 percent. Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’s total net sales increased 28.9 percent. Abbott’s net sales were favorably impacted by changes in foreign exchange rates in the second quarter as the relatively weaker U.S. dollar increased total international sales by 7.0 percent and total sales by 4.5 percent.
The 33.9 percent increase in total net sales during the first six months of 2021, excluding the impact of foreign exchange, reflected demand for Abbott’s tests to detect COVID-19 as well as other growth across Abbott’s reportable segments. During the first six months of 2021, Abbott’s COVID-19 testing-related sales totaled approximately $3.5 billion led by combined sales of approximately $2.8 billion related to Abbott’s BinaxNOW, Panbio, and ID NOW rapid-testing platforms. Excluding the impact of COVID-19 testing-related sales, Abbott’s total net sales increased 19.5 percent. During the first six months of 2020, COVID-19 testing related sales totaled approximately $0.6 billion. Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’s total net sales increased 16.5 percent. Abbott’s net sales were favorably impacted by changes in foreign exchange rates in the first six months as the relatively weaker U.S. dollar increased total international sales by 5.4 percent and total sales by 3.5 percent.
Due to the unpredictability of the duration and impact of the current COVID-19 pandemic, the future extent to which the COVID-19 pandemic will have a material effect on Abbott’s business, financial condition or results of operations is uncertain.
The table below provides detail by sales category for the six months ended June 30. Percent changes are versus the prior year and are based on unrounded numbers.
10.1
(2.3)
12.4
Other Emerging Markets
7.1
3.7
3.4
International Pediatric Nutritionals
1.1
2.5
(1.4)
U.S. Pediatric Nutritionals
International Adult Nutritionals
24.2
2.6
21.6
U.S. Adult Nutritionals
8.9
25.9
21.4
48.0
42.7
1.3
245.7
7.8
237.9
24.1
4.4
19.7
33.7
29.3
16.6
2.1
20.4
4.7
15.7
47.7
5.5
42.2
2.2
37.3
35.1
7.5
27.6
Key Emerging Markets for the Established Pharmaceutical Products business include India, Russia, Brazil and China, along with several other markets that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Excluding the unfavorable effect of foreign exchange, sales in the Key Emerging Markets increased 12.4 percent compared to the first six months of 2020 led by growth across several geographies including India, China and Brazil. Other Emerging Markets, excluding the effect of foreign exchange, increased by 3.4 percent in the first six months of 2021.
International Pediatric Nutritional sales, excluding the effect of foreign exchange, decreased 1.4 percent in the first six months of 2021 versus the comparable 2020 period and the decrease reflects lower sales in China, the Middle East and Canada partially offset by higher volumes sold in various countries in Latin America and Europe. U.S. Pediatric Nutritional sales increased 3.4 percent primarily due to increased demand for Pedialyte®, Abbott’s oral rehydration brand, and Pediasure®. International Adult Nutritional sales, excluding the effect of foreign exchange, increased 21.6 percent, and U.S. Adult Nutritional sales increased 8.9 percent, reflecting continued growth of the Ensure® and Glucerna® brands in several countries including the U.S.
The 84.7 percent increase in Diagnostic Products sales, excluding the impact of foreign exchange, was driven by demand for Abbott’s portfolio of COVID-19 tests as described above as well as growth in the base Core Laboratory and Molecular businesses. In Core Laboratory, sales increased 21.4 percent, excluding the effect of foreign exchange, due to the increased volume of routine diagnostic testing performed in hospitals and other laboratories, partially offset by lower sales of Abbott’s laboratory-based tests for the detection of the IgG and IgM antibodies, which determine if someone was previously infected with the COVID-19 virus. In March 2021, Abbott received an Emergency Use Authorization (EUA) in the U.S. for its AdviseDX SARS-CoV-2 IgG II test for the semi-quantitative detection of IgG antibodies to COVID-19 on its ARCHITECT® and Alinity® i platforms. In the first six months of 2021 and 2020, Core Laboratory IgG and IgM antibody testing-related sales on Abbott’s ARCHITECT and Alinity i platforms were $112 million and $148 million, respectively. In the first six months of 2021, Core Laboratory sales increased 30.0 percent, excluding COVID-19 testing-related sales, and increased 25.1 percent excluding the impact of foreign exchange and COVID-19 testing-related sales.
The 42.7 percent increase in Molecular Diagnostics sales, excluding the effect of foreign exchange, was driven by demand for Abbott’s laboratory-based molecular tests for COVID-19 on its m2000™ and Alinity® m platforms as well as growth in the base business from the continued roll-out of the Alinity m platform. In the first six months of 2021 and 2020, Molecular Diagnostics COVID-19 testing-related sales were $480 million and $312 million,respectively. In March 2021, Abbott received an EUA in the U.S. for its multiplex molecular test on its Alinity m system to detect COVID-19, influenza A, influenza B, and respiratory syncytial virus (RSV) in one test. In the first six months of 2021, Molecular Diagnostics sales increased 37.8 percent, excluding COVID-19 testing-related sales, and increased 34.0 percent excluding the impact of foreign exchange and COVID-19 testing-related sales.
In Rapid Diagnostics, sales increased 237.9 percent, excluding the effect of foreign exchange, due to the demand for Abbott’s COVID-19 tests on its rapid testing platforms including the Panbio system, the ID NOW platform, and the BinaxNOW COVID-19 Ag Card test. In the first six months of 2021 and 2020, Rapid Diagnostics COVID-19 testing-related sales were $2.8 billion and $182 million, respectively. In January 2021, Abbott received CE Mark for two new uses of its Panbio rapid antigen test: asymptomatic testing and self-swabbing under the supervision of a healthcare worker. On March 31, 2021, Abbott announced that it had received an EUA in the U.S. for its over-the-counter, non-prescription BinaxNOW COVID-19 Ag Self Test for individuals with or without symptoms. In the first quarter of 2021, Abbott also received EUAs that allow the non-prescription use of the BinaxNOW COVID-19 Ag Card Home Test and the BinaxNOW COVID-19 Ag Card test for professional use for individuals with or without symptoms. In June 2021, Abbott announced that it had received CE Mark in Europe for its over-the-counter Panbio COVID-19 Antigen Self-Test for individuals with or without symptoms.
Excluding the effect of foreign exchange, total Medical Devices sales grew 25.2 percent driven by double-digit growth across all divisions, led by Diabetes Care, Structural Heart and Electrophysiology. Growth in Diabetes Care sales was driven by continued growth of FreeStyle Libre®, Abbott’s continuous glucose monitoring system, internationally and in the U.S. FreeStyle Libre and Libre Sense® sales totaled $1.733 billion in the first six months of 2021, which reflected a 36.3 percent increase, excluding the effect of foreign exchange, over the first six months of 2020 when Libre sales totaled $1.197 billion. Libre Sense, which received CE Mark in Europe in the third quarter of 2020, is Abbott’s glucose sport biosensor specifically designed for athletes.
24
While procedure volumes across Abbott’s cardiovascular and neuromodulation businesses were negatively impacted early in 2021 by elevated COVID-19 case rates in certain countries, including the U.S., volumes improved over the course of the first six months of 2021 across the various businesses. The year-over-year increases in the various businesses reflect a recovery from the 2020 levels when the pandemic reduced procedure volumes as well as sales growth from pre-pandemic levels in Structural Heart, Electrophysiology, and Heart Failure, excluding the effect of foreign exchange. In January 2021, the U.S. Centers for Medicare & Medicaid Services expanded reimbursement coverage eligibility for MitraClip®, Abbott’s market-leading device for the minimally invasive treatment of mitral regurgitation (MR), a leaky heart valve. The growth in Structural Heart during the first six months of 2021 was broad-based across several areas of the business, including MitraClip, and TriClip®, the world’s first minimally invasive, clip-based device for repair of a leaky tricuspid heart valve which was launched in Europe in May 2020. In May 2021, Abbott announced that it had received CE Mark in Europe for Navitor™, its latest-generation transcatheter aortic valve implantation (TAVI) system for patients with severe aortic stenosis who are at high or extreme surgical risk.
The gross profit margin percentage was 46.7 percent for the second quarter of 2021 compared to 47.9 percent for the second quarter of 2020. The decline in the quarter reflects the impact of the $499 million charge recognized in Cost of products sold in 2021 related to the restructuring plan to align the manufacturing network for COVID-19 diagnostic tests with the change in demand for these tests. The impact of the $499 million charge on gross profit margin was partially offset by the effects of higher sales volume in various businesses, higher utilization at various manufacturing sites and a decrease in amortization expense in 2021. The gross profit margin percentage was 49.9 percent for the first six months of 2021 compared to 49.1 percent for the first six months of 2020. The increase primarily reflects the positive factors that also affected the gross profit margin for the second quarter of 2021, partially offset by the impact of higher restructuring charges in the first six months of 2021.
Research and development expenses increased $90 million, or 15.7 percent, in the second quarter of 2021 and increased $166 million, or 14.5 percent in the first six months of 2021 compared to the prior year. The increases in R&D expenses in the second quarter and first six months of 2021 were primarily driven by higher spending on various projects to advance products in development.
Selling, general and administrative (SG&A) expenses for the second quarter of 2021 increased $450 million, or 19.8 percent, and increased $685 million, or 14.2 percent for the first six months of 2021, due primarily to higher selling and marketing spending to drive growth across various businesses and charges related to certain litigation.
Restructuring Plans
In the second quarter of 2021, Abbott recorded charges of $499 million under this plan in Cost of products sold. The charge recognized in the second quarter includes fixed asset write-downs of $80 million, inventory-related charges of $248 million, and other exit costs, which include contract cancellations and employee-related costs of $171 million. Other exit costs will result in future cash outlays that are expected to be made primarily over the next six months.
Other (Income) Expense, net
Other income, net increased from $22 million of expense in the second quarter of 2020 to $79 million of income in the second quarter of 2021 and from $21 million of expense in the first six months of 2020 to $140 million of income in the first six months of 2021. The increases were primarily due to the nonrecurrence of equity investment impairments that totaled approximately $60 million in the second quarter of 2020 and $110 million in the first six months of 2020, a gain on the sale of an equity method investment in the second quarter of 2021 and higher income in the second quarter and first six months of 2021 related to the non-service cost components of net pension and post-retirement medical benefit costs.
Interest Expense, net
Interest expense, net was virtually unchanged versus the prior year, decreasing $2 million in the second quarter of 2021 and increasing $1 million in the first six months of 2021 as lower interest rates resulted in a decline in interest income that exceeded the reduction in interest expense. The effect of higher cash and short-term investment balances on interest income more than offset the net impact of lower interest rates in the second quarter and mostly offset the impact of lower interest rates in the first six months of 2021.
Taxes on Earnings from Continuing Operations
Liquidity and Capital Resources June 30, 2021 Compared with December 31, 2020
The increase in cash and cash equivalents from $6.8 billion at December 31, 2020 to $8.7 billion at June 30, 2021 primarily reflects the cash generated from operations in the first six months of 2021, partially offset by the payment of dividends, capital expenditures and share repurchases. Working capital was $10.0 billion at June 30, 2021 and $8.5 billion at December 31, 2020. The increase in working capital in 2021 primarily reflects the increase in cash and cash equivalents partially offset by an increase in the current portion of long-term debt.
In the Condensed Consolidated Statement of Cash Flows, Net cash from operating activities for the first six months of 2021 totaled $4.8 billion, an increase of $2.7 billion over the prior year primarily due to higher operating earnings, improved working capital management and the timing of pension contributions partially offset by higher cash taxes paid. Other, net in Net cash from operating activities was a use of $103 million for the first six months of 2021 and a use of $205 million for the first six months of 2020. The year-over-year change in Other, net in Net cash from operating activities is primarily due to the timing of pension contributions as pension contributions were $80 million in 2021 and $335 million in 2020, the payment timing for various accrued expenses associated with litigation and restructuring actions in 2021, and the $80 million non-cash restructuring charge in 2021 to recognize the write-down of COVID-19 manufacturing-related fixed assets, which was partially offset by the higher cash taxes paid in 2021 of approximately $715 million versus the $285 million paid in 2020.
In September 2019, the board of directors authorized the early redemption of up to $5 billion of outstanding long-term notes. As of June 30, 2021, $2.15 billion of the $5 billion authorization remains available.
At June 30, 2021, Abbott’s long-term debt rating was A+ by Standard & Poor’s Corporation and A2 by Moody’s Investors Service. Abbott expects to maintain an investment grade rating. Abbott has readily available financial resources, including lines of credit of $5.0 billion which expire in 2025.
In October 2019, the board of directors authorized the repurchase of up to $3 billion of Abbott’s common shares from time to time. The 2019 authorization was in addition to the approximately $100 million of the share repurchase program authorized in 2014 that remained unused as of December 31, 2020. In June 2021, Abbott repurchased 4.5 million of its common shares for $502 million which fully utilized the authorization remaining under the 2014 share repurchase program and a portion of the 2019 authorization. As of June 30, 2021, $2.595 billion remains available for repurchase under the 2019 share repurchase program.
On April 27, 2016, the board of directors authorized the issuance and sale for general corporate purposes of up to 75 million common shares that would result in proceeds of up to $3 billion. No shares have been issued under this authorization.
In each of the first two quarters of 2021, Abbott declared a quarterly dividend of $0.45 per share on its common shares, which represents an increase of 25 percent over the $0.36 per share dividend declared in each of the first two quarters of 2020.
In December 2019, the Financial Accounting Standards Board issued Accounting Standards Update ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. Abbott adopted the standard on January 1, 2021. The new standard did not have an impact on its condensed consolidated financial statements.
Legislative Issues
Abbott’s primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue over the availability, method of delivery, and payment for health care products and services. It is not possible to predict the extent to which Abbott or the health care industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1, Business, and Item 1A, Risk Factors, in the 2020 Annual Report on Form 10-K.
Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements
Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions that any forward-looking statements made by Abbott are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
PART I. FINANCIAL INFORMATION
PART II. OTHER INFORMATION
Abbott is involved in various claims, legal proceedings and investigations as described in our Annual Report on Form 10-K for the year ended December 31, 2020.
(d) Maximum
Number (or
(c) Total Number
Approximate
of Shares (or
Dollar Value) of
(a) Total
Units) Purchased
Shares (or Units)
Number of
(b) Average
as Part of
that May Yet Be
Shares (or
Price Paid per
Publicly
Purchased Under
Units)
Share (or
Announced Plans
the Plans or
Period
Unit)
or Programs
Programs
April 1, 2021 – April 30, 2021
18,202
(1)
120.900
0
3,097,391,913
(2)
May 1, 2021 – May 31, 2021
(1)
June 1, 2021 – June 30, 2021
4,500,000
111.575
2,595,306,483
4,518,202
111.612
These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.
Exhibit No.
Exhibit
31.1
Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
31.2
Certification of Chief Financial Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.
32.1
Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2
Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101
The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter and six months ended June 30, 2021, formatted in Inline XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed Consolidated Statement of Comprehensive Income; (iii) Condensed Consolidated Balance Sheet; (iv) Condensed Consolidated Statement of Shareholders’ Investment; (v) Condensed Consolidated Statement of Cash Flows; and (vi) Notes to the Condensed Consolidated Financial Statements.
104
Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document and included in Exhibit 101).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
By:
/s/ Robert E. Funck, Jr.
Robert E. Funck, Jr.
Executive Vice President, Financeand Chief Financial Officer
Date: August 4, 2021